We read with interest the article by Taneja et al. We believe that it was a great effort considering the number of studies on this particular group and no such study in our population group. There is relatively low awareness about these ophthalmic manifestations of thalassemia and this article would go a long way to create awareness about the same.
We want to share our own experience (presented as a free paper in AIOC 2009, Jaipur) which is different from their findings, especially in the untreated and treated group with desferioxamine. A total of 112 children (224 eyes) with beta thalassemia were taken for the study. Ninety-five children (190 eyes, 84.8%) not on desferioxamine therapy were termed as case group and 17 children (34 eyes, 15.2%) were on desferioxamine and called control group. Out of 95 children, 62 (65.2%) were male. All children were under the age of 15 years (4-15 years) who had received multiple blood transfusions.
Conjunctival blanching and isolated cataractous changes in the lens were the most common anterior segment findings in the untreated group. Both were found in 12 (6.3%) eyes. The rest of the findings are listed in Table 1. In the group on desferioxamine, none of these children had any opacity in the lens. Four (11.8%) had tessellated fundus in the control group.
The ocular manifestations were compared in the untreated group with respect to serum ferritin [Table 2]. We compared our data with other studies and found lens opacities were commoner in our study (14 eyes 7.3%).
Goldberg et al. did not find a single case with lens opacity. However, his patients were mainly with sickle cell hemoglobinopathy and not beta thalassemia patients. Degeneration of retinal pigment epithelium (RPE) and tessellated fundus were common in our study as has been noted in a previous study by Gartaganis et al.
We could not find a single case with angioid streaks even when our case series was larger. We saw untreated cases and therefore, could see that the effects on the eye were mainly because of the iron overload and not secondary to chelating therapy as has been thought.
We could not find a single case of lens opacities in children (small sample size) with reduced serum ferritin levels. All these children were on chelating therapy. Ocular manifestation in control group was significantly lower and it was comparable to other studies. This suggests that serum ferritin levels and iron load may not be actually responsible for the ocular manifestations of beta thatlessemia. Our study absolves desferioxamine of any role in causing ocular surface disorders. Rather, it is the disease itself which may be responsible for any such disorder. Desferioxamine may be considered safe so far as the eye is concerned. However, since our sample size was small, such results should be interpreted with caution.
1. Taneja R, Malik P, Sharma M, Agarwal MC. Multiple transfused thalassemia major: Ocular manifestations in a hospital based population Indian J Ophthalmol. 2010;58:125–30
2. Gartaganis S, Ismiridis K, Papageorgiou O, Beratis NG, Papanastasiou D. Ocular abnormalities in patients with beta thalassemia Am J Ophthalmol. 1989;108:699–703
3. Goldberg MF, Charache S, Acacio I. Ophthalmologic manifestations of sickle cell thalassemia Arch Intern Med. 1971;128:33–9